<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01705379</url>
  </required_header>
  <id_info>
    <org_study_id>V59_45OB</org_study_id>
    <nct_id>NCT01705379</nct_id>
  </id_info>
  <brief_title>Safety of One Dose of Meningococcal ACWY Conjugate Vaccine in Subjects 2 Years of Age and Older</brief_title>
  <official_title>A Multicenter, Single Arm, Post Marketing Surveillance Study to Monitor the Safety of Novartis Meningococcal ACWY Conjugate Vaccine (MenACWY-CRM) Administered According to the Prescribing Information to Healthy Subjects 2 Years of Age and Older in the Philippines</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicenter, single arm, postmarketing surveillance study. This study is a postlicensure
      requirement of the Philippine Food and Drug Administration (FDA) to provide continued safety
      evaluation of MenACWY-CRM in Philippine individuals 2 years of age and older, receiving
      MenACWY-CRM vaccination according to routine clinical practice and prescribing information.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">April 2016</completion_date>
  <primary_completion_date type="Anticipated">April 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>All adverse events</measure>
    <time_frame>Day 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>All serious adverse events</measure>
    <time_frame>Day 29</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">0</enrollment>
  <condition>Meningococcal Disease</condition>
  <arm_group>
    <arm_group_label>MenACWY-CRM</arm_group_label>
    <description>2 years of age and older</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Novartis Meningococcal ACWY Conjugate Vaccine</intervention_name>
    <description>Immunization</description>
    <arm_group_label>MenACWY-CRM</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy male and female subjects 2 years of age and older
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Individuals eligible for enrolment in this study are those:

          1. who are of any gender, from the age of 2 and older, and to whom/whose parents or
             legally acceptable representatives the nature of the study has been described and the
             subject/subject's parent/legally acceptable representative has provided written
             informed consent.

          2. who the investigator believes that the subject and/or his or her parent/legal
             representative can and will comply with the requirements of the protocol.

          3. who are in good health as determined by clinical judgment of the investigator.

        Exclusion Criteria:

        Individuals not eligible to be enrolled in the study are those:

          1. who are unwilling or unable to give written informed consent or assent to participate
             in the study.

          2. who are perceived to be unreliable or unavailable for the duration of the study
             period.

          3. who have previously been immunized with a meningococcal vaccine or vaccine containing
             meningococcal antigen(s) (licensed or investigational).

          4. who have received any investigational or non-registered product (drug or vaccine)
             within 30 days prior to enrolment or who expect to receive an investigational drug or
             vaccine prior to the completion of the study.

          5. who have received or who are planning to receive any vaccines (other than routine
             childhood vaccines) within 30 days before and after administration of study vaccine.

             (Exception: Influenza vaccine may be administered up to 15 days prior to study
             vaccination and at least 15 days after study vaccination)

          6. who have behavioral or cognitive impairment or psychiatric disease that, in the
             opinion of the investigator, may interfere with the subject's ability to participate
             in the study.

          7. who are pregnant or breast feeding (female subjects of appropriate age) or who plan to
             become pregnant during the course of the study.

          8. who have any serious acute, chronic or progressive disease (e.g., any history of
             neoplasm, cancer, diabetes, cardiac disease, autoimmune disease, HIV infection or
             AIDS, or blood dyscrasias, with signs of cardiac or renal failure or severe
             malnutrition), who have epilepsy or any progressive neurological disease or history of
             Guillain-Barre syndrome.

          9. who have a history of any anaphylaxis, serious vaccine reactions, or allergy to any
             vaccine components.

         10. who are known to have a bleeding diathesis, or any condition that may be associated
             with a prolonged bleeding time.

         11. who are included in study personnel or close family members of personnel conducting
             this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 9, 2012</study_first_submitted>
  <study_first_submitted_qc>October 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2012</study_first_posted>
  <last_update_submitted>November 30, 2016</last_update_submitted>
  <last_update_submitted_qc>November 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neisseria meningitidis, conjugate vaccine, phase IV clinical trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Lactitol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

